Antiretrovirals
US treatment guidelines updated – March 2004
The US Department of Health and Human Services updated its adult antiretroviral treatment guidelines on 23 March 2004.
The following changes have been made to recommended regimens for ARV-naïve patients:
- Fosamprenavir and ritonavir-boosted fosamprenavir are added as options for PI-based regimens and amprenavir and unboosted indinavir have been removed
- Abacavir plus lamivudine has been added as an alternative 2-NRTI backbone.
New safety information regarding the risks of nevirapine-associated symptomatic hepatic events has been added to the text of the guidelines (sections on “NNRTI-Based Regimens” and “Hepatotoxicity”) and the respective tables (Tables 12a, 12b, and 19).
Characteristics and drug interaction information for fosamprenavir have been added to the respective tables (Tables 17, 20, 21, 22a, 22b, 23, and 30).
A new table of antiretroviral dosing recommendations for patients with renal or hepatic dysfunction has been created (Table 13).
Link:
Links to external websites are current at time of posting but not maintained.